Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John de Groot

Showing results (41-50 of 87) with videos related to

Pageof 9
Sort By:
Neuro-Oncology|October 17, 2017
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapyTimothy F Cloughesy, Jan Drappatz, John de Groot, et al.
Neuro-Oncology|October 11, 2017
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapyPatrick Y Wen, Jan Drappatz, John de Groot, et al.
Neurosurgery|February 18, 2022
Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective StudyAntonio Dono, Kristin Alfaro-Munoz, Yuanqing Yan, et al.
Neuro-Oncology|July 3, 2016
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignanciesSarah T Garber, Yuuri Hashimoto, Shiao-Pei Weathers, et al.
Cancer|June 3, 2020
Long-term survival among 5-year survivors of adolescent and young adult cancerAmy M Berkman, J A Livingston, Kelly Merriman, et al.
The Lancet. Oncology|March 29, 2023
Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials ConferenceRifaquat Rahman, Mei-Yin C Polley, Laura Alder, et al.
Neuro-Oncology|August 24, 2010
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastomaMark R Gilbert, Javier Gonzalez, Kathy Hunter, et al.
Research Square|April 16, 2025
Spatial synaptic connectivity underlies oligodendroglioma evolution and recurrenceDavid Raleigh, Kanish Mirchia, Sena Oten, et al.
Targeted Oncology|January 25, 2013
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with afliberceptNicole Shonka, Yuji Piao, Mark Gilbert, et al.
Journal of Neurosurgery|October 7, 2017
Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539Leland Rogers, Peixin Zhang, Michael A Vogelbaum, et al.
Pageof 9

Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
Neuro-Oncology|October 17, 2017
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapyTimothy F Cloughesy, Jan Drappatz, John de Groot, et al.
Neuro-Oncology|October 11, 2017
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapyPatrick Y Wen, Jan Drappatz, John de Groot, et al.
Neurosurgery|February 18, 2022
Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective StudyAntonio Dono, Kristin Alfaro-Munoz, Yuanqing Yan, et al.
Neuro-Oncology|July 3, 2016
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignanciesSarah T Garber, Yuuri Hashimoto, Shiao-Pei Weathers, et al.
Cancer|June 3, 2020
Long-term survival among 5-year survivors of adolescent and young adult cancerAmy M Berkman, J A Livingston, Kelly Merriman, et al.
The Lancet. Oncology|March 29, 2023
Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials ConferenceRifaquat Rahman, Mei-Yin C Polley, Laura Alder, et al.
Neuro-Oncology|August 24, 2010
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastomaMark R Gilbert, Javier Gonzalez, Kathy Hunter, et al.
Research Square|April 16, 2025
Spatial synaptic connectivity underlies oligodendroglioma evolution and recurrenceDavid Raleigh, Kanish Mirchia, Sena Oten, et al.
Targeted Oncology|January 25, 2013
Cytokines associated with toxicity in the treatment of recurrent glioblastoma with afliberceptNicole Shonka, Yuji Piao, Mark Gilbert, et al.
Journal of Neurosurgery|October 7, 2017
Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539Leland Rogers, Peixin Zhang, Michael A Vogelbaum, et al.
Pageof 9